MX2024006300A - Inhibidores de aminoheteroaril cinasa. - Google Patents

Inhibidores de aminoheteroaril cinasa.

Info

Publication number
MX2024006300A
MX2024006300A MX2024006300A MX2024006300A MX2024006300A MX 2024006300 A MX2024006300 A MX 2024006300A MX 2024006300 A MX2024006300 A MX 2024006300A MX 2024006300 A MX2024006300 A MX 2024006300A MX 2024006300 A MX2024006300 A MX 2024006300A
Authority
MX
Mexico
Prior art keywords
aminoheteroaryl
kinase inhibitors
compounds
cdks
disorders
Prior art date
Application number
MX2024006300A
Other languages
English (en)
Spanish (es)
Inventor
Tao Zhang
Dai Cheng
Qiang Ding
Original Assignee
Allorion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allorion Therapeutics Inc filed Critical Allorion Therapeutics Inc
Publication of MX2024006300A publication Critical patent/MX2024006300A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/20—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hydrogen atoms and substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D309/22—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Control Of El Displays (AREA)
MX2024006300A 2020-11-27 2022-11-23 Inhibidores de aminoheteroaril cinasa. MX2024006300A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2020132454 2020-11-27
CN2021081236 2021-03-17
PCT/CN2021/133429 WO2022111621A1 (en) 2020-11-27 2021-11-26 Aminoheteroaryl kinase inhibitors
PCT/CN2022/133770 WO2023093769A1 (en) 2020-11-27 2022-11-23 Aminoheteroaryl kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2024006300A true MX2024006300A (es) 2024-07-24

Family

ID=81753779

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024006300A MX2024006300A (es) 2020-11-27 2022-11-23 Inhibidores de aminoheteroaril cinasa.

Country Status (10)

Country Link
US (2) US20240166635A1 (cg-RX-API-DMAC10.html)
EP (2) EP4251613A4 (cg-RX-API-DMAC10.html)
JP (2) JP7895947B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230127228A (cg-RX-API-DMAC10.html)
CN (3) CN122483000A (cg-RX-API-DMAC10.html)
AU (3) AU2021385745C1 (cg-RX-API-DMAC10.html)
CA (2) CA3202990A1 (cg-RX-API-DMAC10.html)
IL (1) IL303237A (cg-RX-API-DMAC10.html)
MX (1) MX2024006300A (cg-RX-API-DMAC10.html)
WO (2) WO2022111621A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4251613A4 (en) * 2020-11-27 2024-11-20 Allorion Therapeutics Inc. AMINOHETEROARYL KINASE INHIBITORS
US20250009745A1 (en) * 2021-02-05 2025-01-09 Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. Cdk inhibitor
CN119343333A (zh) * 2022-05-27 2025-01-21 安锐生物医药公司 氨基杂芳基激酶抑制剂
WO2025006400A1 (en) * 2023-06-25 2025-01-02 Allorion Therapeutics Inc Isotopologues of aminoheteroaryl kinase inhibitors and uses thereof
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers
EP4725942A1 (en) * 2024-10-09 2026-04-15 Sibylla Biotech S.p.A. Compounds active on cyclin d1 pathway and their use

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004890D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0016877D0 (en) * 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
GB0021726D0 (en) * 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
MXPA03005696A (es) * 2000-12-21 2003-10-06 Glaxo Group Ltd Pirimidinaminas como moduladores de angiogenesis.
IL159120A0 (en) * 2001-05-29 2004-05-12 Schering Ag Cdk inhibiting pyrimidines, production thereof and their use as medicaments
GB0113041D0 (en) * 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
HUP0402245A3 (en) * 2001-11-01 2010-03-29 Janssen Pharmaceutica Nv Pyrimidinyl-aminobenzamide derivatives as glycogen synthase kinase 3betha inhibitors, their use, pharmaceutical compositions containing them and process for producing them
GB0205693D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205688D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
JP2005526765A (ja) 2002-03-11 2005-09-08 シエーリング アクチエンゲゼルシャフト Cdk−阻害性2−ヘテロアリール−ピリミジン類、それらの生成及び医薬としての使用
WO2004048343A1 (en) * 2002-11-28 2004-06-10 Schering Aktiengesellschaft Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
DE102005008310A1 (de) * 2005-02-17 2006-08-24 Schering Ag Verwendung von CDKII Inhibitoren zur Fertilitätskontrolle
ATE541848T1 (de) * 2005-05-05 2012-02-15 Ardea Biosciences Inc Diaryl-purin, azapurine und deazapurine als nichtnukleoside reverse-transkriptase-inhibitoren zur behandlung von hiv
AU2007338792B2 (en) * 2006-12-20 2012-05-31 Amgen Inc. Substituted heterocycles and methods of use
EP2142550A1 (en) * 2007-04-02 2010-01-13 Palau Pharma, S.A. Pyrrolopyrimidine derivatives as jak3 inhibitors
MX2009011199A (es) 2007-04-16 2010-03-17 Hutchison Medipharma Entpr Ltd Derivados de pirimidina.
DK2146779T3 (en) * 2007-04-18 2016-11-28 Pfizer Prod Inc Sulfonylamid derivatives to treat abnormal cell growth.
WO2009022171A1 (en) 2007-08-13 2009-02-19 Astrazeneca Ab Pyridinyiioxy pyridines as alk5 inhibitors
EP2179992A1 (de) * 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Sulfonsubstituierte Anlinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
TW201024281A (en) * 2008-11-24 2010-07-01 Boehringer Ingelheim Int New compounds
DE102010014426A1 (de) * 2010-04-01 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
US9145402B2 (en) * 2011-11-29 2015-09-29 Genentech, Inc. Aminopyrimidine derivatives as LRRK2 modulators
NZ629830A (en) * 2014-07-14 2015-12-24 Signal Pharm Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
CN110386901B (zh) 2018-04-23 2022-11-25 上海医药工业研究院 含磺酰苯胺嘧啶结构的化合物及其作为抗肿瘤药物的应用
US12037323B2 (en) 2018-05-03 2024-07-16 Bristol-Myers Squibb Company Uracil derivatives as Mer-AXL inhibitors
US11919904B2 (en) * 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
JP2023515629A (ja) * 2020-02-28 2023-04-13 フォチョン・バイオサイエンシーズ・リミテッド Cdk2/4/6阻害剤としての化合物
WO2022096473A1 (en) * 2020-11-04 2022-05-12 Umicore A positive electrode active material for rechargeable batteries
EP4251613A4 (en) * 2020-11-27 2024-11-20 Allorion Therapeutics Inc. AMINOHETEROARYL KINASE INHIBITORS
US20250009745A1 (en) * 2021-02-05 2025-01-09 Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. Cdk inhibitor

Also Published As

Publication number Publication date
EP4251613A4 (en) 2024-11-20
CA3238970A1 (en) 2023-06-01
AU2021385745A9 (en) 2025-03-27
CN116528869B (zh) 2026-04-14
AU2025200001A1 (en) 2025-01-23
EP4251613A1 (en) 2023-10-04
KR20230127228A (ko) 2023-08-31
AU2021385745C1 (en) 2025-02-20
EP4436959A1 (en) 2024-10-02
JP2024506116A (ja) 2024-02-09
CN118475562A (zh) 2024-08-09
EP4436959A4 (en) 2026-02-11
AU2022397678A1 (en) 2024-05-30
CA3202990A1 (en) 2022-06-02
US20250002480A1 (en) 2025-01-02
WO2022111621A1 (en) 2022-06-02
IL303237A (en) 2023-07-01
JP7895947B2 (ja) 2026-07-28
CN122483000A (zh) 2026-07-31
AU2021385745A1 (en) 2023-06-15
US20240166635A1 (en) 2024-05-23
AU2021385745B2 (en) 2024-10-03
JP2024541533A (ja) 2024-11-08
WO2023093769A1 (en) 2023-06-01
CN116528869A (zh) 2023-08-01

Similar Documents

Publication Publication Date Title
MX2025011774A (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
MX2020014245A (es) Inhibidores de quinasas dependientes de ciclinas.
MX2025002487A (es) Aminas biciclicas como inhibidores de la cinasa dependiente de ciclina 2 (cdk2)
JOP20230272A1 (ar) مركبات تثبيط rip1 وطرق لتحضير واستخدامها
AU2020281332A8 (en) Dna-dependent protein kinase inhibitor
ZA202204284B (en) Inhibitors of raf kinases
JOP20200277B1 (ar) مركبات تثبيط rip1 وطرق لتحضير واستخدامها
WO2020093006A8 (en) Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (cdk7)
PH12023552079A1 (en) Cdk2 inhibitors and methods of using the same
MX382938B (es) Derivados de 2-h-indazol como inhibidores de kinasas dependientes de ciclinas (cdk) y usos terapéuticos de los mismos.
SA522441624B1 (ar) مثبطات إنزيمات كيناز مستقبل عامل نمو الأرومة الليفية
MX2025001108A (es) Inhibidores de cinasas aminoheteroarílicos.
MX2024015581A (es) Derivados de anilino-pirazol, composiciones y metodos de estos
PH12021551304A1 (en) Tyrosine kinase inhibitors, compositions and methods there of
PH12022551623A1 (en) Substituted pyrazolo-pyrimidines and uses thereof
MX2023003516A (es) Inhibidores no covalentes de la cinasa dependiente de ciclina 7 (cdk7).
GB201302704D0 (en) Therapeutic compounds
MX2025009633A (es) Inhibidores de quinasa dependientes de ciclina (cdk2)
JOP20220355A1 (ar) مثبطات rip1k
MX2024013266A (es) Compuestos de 6-(pirimidin-4-il)quinolina sustituidos como inhibidores de la cinasa dependiente de ciclina
MX2017014752A (es) Nuevos etinos de amidoheteroaril aroil hidrazida.
MX2025013034A (es) Inhibidores de egfr para el tratamiento de enfermedades
GEP20227437B (en) 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
MX2022001702A (es) Inhibidores de jak.
JOP20230213A1 (ar) مثبطات حلقية غير متجانسة لكيناز البروتين المتفاعل مع المستقبل-1